• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

?
-

Resources for You

January 9, 2009 Approval Letter - Menomune-A/C/Y/W-135

 

Our STN: BL 103926/5099

Attn: Gary K. Chikami, M.D.
Sanofi Pasteur, Inc.
Discovery Drive
Swiftwater, PA 18370

Dear Dr. Chikami:

We have approved your request to supplement your biologics license application for Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined (Menomune®-A/C/Y/W-135) to revise the package insert to include additional safety and immunogenicity data from clinical trials and to update information on spontaneously reported adverse events.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence to support that claim.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

/signature/

Wellington Sun, MD
Director
Division of Vaccines and Related
Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Attachment: Approved Final Draft Labeling